Tucker, April N <br/><br/>
Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients.  [electronic resource] 

 -  Cancer letters  Jan 2005 
 - 61-72 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>0304-3835 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2004.08.027  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Black or African American<br/>Aged<br/>Antineoplastic Agents, Hormonal--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Cytochrome P-450 CYP3A<br/>Cytochrome P-450 Enzyme System--genetics<br/>Female<br/>Humans<br/>Middle Aged<br/>Polymerase Chain Reaction<br/>Polymorphism, Genetic<br/>Postmenopause<br/>Tamoxifen--adverse effects<br/>White People